These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers. Suto F; Rowe-Rendleman CL; Ouchi T; Jamil A; Wood A; Ward CL Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):7963-70. PubMed ID: 26720443 [TBL] [Abstract][Full Text] [Related]
5. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Schachar RA; Raber S; Courtney R; Zhang M Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167 [TBL] [Abstract][Full Text] [Related]
6. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940 [TBL] [Abstract][Full Text] [Related]
7. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Williams RD; Novack GD; van Haarlem T; Kopczynski C; Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845 [TBL] [Abstract][Full Text] [Related]
8. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Denis P; Andrew R; Wells D; Friren B Eur J Ophthalmol; 2006; 16(3):407-15. PubMed ID: 16761242 [TBL] [Abstract][Full Text] [Related]
9. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T; Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500 [TBL] [Abstract][Full Text] [Related]
10. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Konstas AG; Mikropoulos D; Kaltsos K; Jenkins JN; Stewart WC Ophthalmology; 2006 Mar; 113(3):446-50. PubMed ID: 16513458 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study. García-López A; Paczka JA; Jiménez-Román J; Hartleben C BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295 [TBL] [Abstract][Full Text] [Related]
12. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study. Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275 [TBL] [Abstract][Full Text] [Related]
14. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002 [TBL] [Abstract][Full Text] [Related]
15. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt). Brinzolamide Dose-Response Study Group. Silver LH Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S147-53. PubMed ID: 10665517 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946 [TBL] [Abstract][Full Text] [Related]
17. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension. Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098 [TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081 [TBL] [Abstract][Full Text] [Related]
19. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC; Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013 [TBL] [Abstract][Full Text] [Related]